Skip to Main Content


  • Autoimmune disease where antibodies are produced to the (postsynaptic) acetylcholine (ACh) receptor of neuromuscular junction (NMJ), possibly originating in thymus
  • Ten percent of patients have congenital myasthenia with abnormal ACh receptors; cholinesterase inhibitors will be ineffective in these patients
  • Results in functionally decreased (70–80%) number of postsynaptic receptors
  • Incidence of about 1:10,000
  • Before age of 40 years, 2F/1M, 40% thymus enlargement
  • After age of 40 years, 1F/1M, 20% thymoma
  • Most commonly affects ocular muscles, but can affect any skeletal muscle, including muscles of respiration
  • Characterized by skeletal muscle weakness that improves with rest
  • Clinical course often marked by periods of exacerbations and remissions
  • Treatment:
    • Cholinesterase inhibitors to increase amount of ACh at NMJ
    • Corticosteroids
    • Immunosuppression (mycophenolate mofetil, azathioprine, cyclosporine, tacrolimus, and occasionally cyclophosphamide)
    • Plasmapheresis to remove antibodies, IVIg
    • Thymectomy
  • Pregnancy:
    • Worsening in first 4 months, at delivery, and postpartum (up to 3 weeks)
    • Optimize therapy; immunosuppressants are contraindicated
    • Epidural for delivery or c/s; avoid high level; consider ropivacaine (less motor block)
    • Breastfeeding OK if well controlled
    • Neonatal myasthenia (antibodies cross placenta) in 20–30%: weak cry, difficulty feeding, occasional respiratory distress; treat with cholinesterase inhibitors, plasmapheresis

Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print
Differences between Eaton–Lambert Syndrome and Myasthenia Gravis
SyndromeMyasthenia gravisEaton–Lambert syndrome
Association with cancerNot associated with cancer
  • Usually small cell lung cancer (SCLC), but also non-SCLC, lymphosarcoma, malignant thymoma, or carcinoma of the breast, stomach, colon, prostate, bladder, kidney, or gallbladder
  • Clinical manifestations often precede cancer diagnosis by 2–4 years
PathophysiologyAutoimmune attack directed against the postsynaptic acetylcholine receptor, results in impaired ACh effect at the NMJ
  • Autoimmune attack directed against the voltage-gated calcium channels (VGCCs) on the presynaptic motor nerve terminal results in impaired ACh release
  • Parasympathetic, sympathetic, and enteric neurons are all affected
Clinical diagnosis
  • Increasing weakness with repeated effort
  • Improvement with rest
  • Increasing strength with repeated effort
  • Reappearance of tendon reflexes after a period of muscle contraction by the patient
  • Relatively common
  • Bimodal distribution (see above)
  • Rare (˜400 cases in the United States at any given time)
  • Typically in >60 years old, but has been reported in children
Autonomic findingsNoneDysautonomia: dryness of the mouth, impotence, difficulty in starting the urinary stream, and constipation
Treatment (besides supportive)See below
  • Treatment of underlying neoplasm
  • Cholinesterase inhibitors
  • 3,4-Diaminopyridine
  • Immunosuppression with corticosteroids, IVIg, guanidine, aminopyridines, and azathioprine
Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print
Main Cholinesterase Inhibitors Used to Treat MG
MedicationOnset/durationTypical dosageSide effects
Pyridostigmine (Mestinon)PO: 15–30 min/3–4 hPO: 60 mg qidMuscarinic side effects (diarrhea, abdominal cramps, salivation, nausea), treated with atropine/diphenoxylate or loperamide
Neostigmine (Prostigmin)
  • PO: 1 h/90 min
  • IM: 30 min/1 h
  • IV: immediate/20 min
  • PO: 15 mg
  • IM: 1.5 mg
  • IV: 0.5 mg
Ambenonium (Mytelase)PO: 20–30 min/3–8 hPO: 5–25 mg qidSame
Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print
Severity: Osserman–Genkins Classification...
Stage IOcular symptoms only (diplopia, ptosis)
Stage IIA

Want remote access to your institution's subscription?

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.


About MyAccess

If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.

Subscription Options

AccessAnesthesiology Full Site: One-Year Subscription

Connect to the full suite of AccessAnesthesiology content and resources including procedural videos, interactive self-assessment, real-life cases, 20+ textbooks, and more

$995 USD
Buy Now

Pay Per View: Timed Access to all of AccessAnesthesiology

24 Hour Subscription $34.95

Buy Now

48 Hour Subscription $54.95

Buy Now

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.